Oesterle Stephen N. 4
4 · Sigilon Therapeutics, Inc. · Filed May 27, 2022
Insider Transaction Report
Form 4
OESTERLE STEPHEN N
Director
Transactions
- Award
Stock Option (Right to Buy)
2022-05-26+8,888→ 8,888 totalExercise: $0.76Exp: 2032-05-25→ Common Stock (8,888 underlying)
Footnotes (1)
- [F1]The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023.